These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 29915160)

  • 21. That which does not kill me makes me stronger; combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance.
    Sale MJ; Cook SJ
    Br J Pharmacol; 2013 Aug; 169(8):1708-22. PubMed ID: 23647573
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
    Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
    Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MEK1 mutations confer resistance to MEK and B-RAF inhibition.
    Emery CM; Vijayendran KG; Zipser MC; Sawyer AM; Niu L; Kim JJ; Hatton C; Chopra R; Oberholzer PA; Karpova MB; MacConaill LE; Zhang J; Gray NS; Sellers WR; Dummer R; Garraway LA
    Proc Natl Acad Sci U S A; 2009 Dec; 106(48):20411-6. PubMed ID: 19915144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation.
    Wang H; Daouti S; Li WH; Wen Y; Rizzo C; Higgins B; Packman K; Rosen N; Boylan JF; Heimbrook D; Niu H
    Cancer Res; 2011 Aug; 71(16):5535-45. PubMed ID: 21705440
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer.
    Queralt B; Cuyàs E; Bosch-Barrera J; Massaguer A; de Llorens R; Martin-Castillo B; Brunet J; Salazar R; Menendez JA
    Oncotarget; 2016 Dec; 7(50):82185-82199. PubMed ID: 27636997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
    Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
    Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantifying single-cell ERK dynamics in colorectal cancer organoids reveals EGFR as an amplifier of oncogenic MAPK pathway signalling.
    Ponsioen B; Post JB; Buissant des Amorie JR; Laskaris D; van Ineveld RL; Kersten S; Bertotti A; Sassi F; Sipieter F; Cappe B; Mertens S; Verlaan-Klink I; Boj SF; Vries RGJ; Rehmann H; Vandenabeele P; Riquet FB; Trusolino L; Bos JL; Snippert HJG
    Nat Cell Biol; 2021 Apr; 23(4):377-390. PubMed ID: 33795873
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers.
    Temraz S; Mukherji D; Shamseddine A
    Int J Mol Sci; 2015 Sep; 16(9):22976-88. PubMed ID: 26404261
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer.
    Zhang P; Kawakami H; Liu W; Zeng X; Strebhardt K; Tao K; Huang S; Sinicrope FA
    Mol Cancer Res; 2018 Mar; 16(3):378-389. PubMed ID: 29233910
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Copper Chelation Inhibits BRAF
    Brady DC; Crowe MS; Greenberg DN; Counter CM
    Cancer Res; 2017 Nov; 77(22):6240-6252. PubMed ID: 28986383
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ERK1/2 can feedback-regulate cellular MEK1/2 levels.
    Hong SK; Wu PK; Karkhanis M; Park JI
    Cell Signal; 2015 Oct; 27(10):1939-48. PubMed ID: 26163823
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oncogenic KRAS signalling promotes the Wnt/β-catenin pathway through LRP6 in colorectal cancer.
    Lemieux E; Cagnol S; Beaudry K; Carrier J; Rivard N
    Oncogene; 2015 Sep; 34(38):4914-27. PubMed ID: 25500543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MEK1/2 inhibition decreases lactate in BRAF-driven human cancer cells.
    Falck Miniotis M; Arunan V; Eykyn TR; Marais R; Workman P; Leach MO; Beloueche-Babari M
    Cancer Res; 2013 Jul; 73(13):4039-49. PubMed ID: 23639941
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential responses of human papillary thyroid cancer cell lines carrying the RET/PTC1 rearrangement or a BRAF mutation to MEK1/2 inhibitors.
    Henderson YC; Fredrick MJ; Clayman GL
    Arch Otolaryngol Head Neck Surg; 2007 Aug; 133(8):810-5. PubMed ID: 17709622
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
    Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
    Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy.
    Mandal R; Becker S; Strebhardt K
    Oncogene; 2016 May; 35(20):2547-61. PubMed ID: 26364606
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of immunoglobulin transcription factor 2 and resistance to MEK inhibitor in melanoma cells.
    Hur EH; Goo BK; Moon J; Choi Y; Hwang JJ; Kim CS; Bae KS; Choi J; Cho SY; Yang SH; Seo J; Lee G; Lee JH
    Oncotarget; 2017 Jun; 8(25):41387-41400. PubMed ID: 28574827
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RASSF7 promotes cell proliferation through activating MEK1/2-ERK1/2 signaling pathway in hepatocellular carcinoma.
    Zhang M; Li Q; Zhang L; Wang Y; Wang L; Li Q; He T; Wan B; Wang X
    Cell Mol Biol (Noisy-le-grand); 2018 Apr; 64(5):73-79. PubMed ID: 29729697
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.
    Arqués O; Chicote I; Puig I; Tenbaum SP; Argilés G; Dienstmann R; Fernández N; Caratù G; Matito J; Silberschmidt D; Rodon J; Landolfi S; Prat A; Espín E; Charco R; Nuciforo P; Vivancos A; Shao W; Tabernero J; Palmer HG
    Clin Cancer Res; 2016 Feb; 22(3):644-56. PubMed ID: 26224873
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanistic Analysis of an Extracellular Signal-Regulated Kinase 2-Interacting Compound that Inhibits Mutant BRAF-Expressing Melanoma Cells by Inducing Oxidative Stress.
    Martinez R; Huang W; Samadani R; Mackowiak B; Centola G; Chen L; Conlon IL; Hom K; Kane MA; Fletcher S; Shapiro P
    J Pharmacol Exp Ther; 2021 Jan; 376(1):84-97. PubMed ID: 33109619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.